Naloxone nasal spray - Adapt Pharma/Opiant Pharmaceuticals

Drug Profile

Naloxone nasal spray - Adapt Pharma/Opiant Pharmaceuticals

Alternative Names: LT-12; LT-20; LT-21; LT-22; Naloxon B; Naloxone HCl; NARCAN Nasal Spray; Narcan Nasal Spray; OPNT 001

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lightlake Therapeutics
  • Developer Adapt Pharma; National Institute on Drug Abuse; Opiant Pharmaceuticals; University of Pennsylvania
  • Class Antidotes; Morphinans; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Opioid abuse
  • Phase II Bulimia nervosa; Cocaine abuse; Eating disorders
  • Phase I Drug abuse

Most Recent Events

  • 22 Feb 2018 Aegis Therapeutics has patent protection for fast acting nasal spray opioid blockers and pain medications in USA
  • 30 Jun 2017 An Interim Order, signed by Health Canada, expires on July 5, 2017
  • 27 Jun 2017 Naloxone nasal spray enlisted in US FDA Orange Book
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top